Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats

about

Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats

Item

http://www.wikidata.org/entity/Q58866635

description

im Februar 2008 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 February 2008

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2008

@uk

name

Pharmacokinetics and brain upt ...... avenous administration to rats

@en

Pharmacokinetics and brain upt ...... avenous administration to rats

@nl

type

Item

label

Pharmacokinetics and brain upt ...... avenous administration to rats

@en

Pharmacokinetics and brain upt ...... avenous administration to rats

@nl

prefLabel

Pharmacokinetics and brain upt ...... avenous administration to rats

@en

Pharmacokinetics and brain upt ...... avenous administration to rats

@nl

P1476

Pharmacokinetics and brain upt ...... avenous administration to rats

@en

P2093

Bevyn Jarrott

http://www.w3.org/2001/XMLSchema#string

Gregg Smith

http://www.w3.org/2001/XMLSchema#string

Jennifer K Callaway

http://www.w3.org/2001/XMLSchema#string

Jessica A Steuten

http://www.w3.org/2001/XMLSchema#string

Joseph A Nicolazzo

http://www.w3.org/2001/XMLSchema#string

Kasiram Katneni

http://www.w3.org/2001/XMLSchema#string

Tien T Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis

Designing libraries with CNS activity.

Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.

AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischaemia.

Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.

In vitro models for the blood-brain barrier.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics.

AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion.

Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors.

P304

171-178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1211/JPP.60.2.0005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Susan A. Charman

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18237464

http://www.w3.org/2001/XMLSchema#string